RIGL Overview
Upcoming Projects (RIGL)
Executed Projects (RIGL)
-
A Second View: Looking at fostamatinib ahead of the phase 3 readout in WAIHA
Ticker: RIGL
Executed On: Apr 06, 2022 at 05:00 PM EDT -
An updated look at fostamatinib ahead of the phase 3 readout in WAIHA
Ticker: RIGL
Executed On: Mar 29, 2022 at 10:00 AM EDT
Upcoming & Overdue Catalysts (RIGL)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (RIGL)
-
FDA Decision Regarding Rigel's (RIGL) New Drug Application for Fostamatinib in Chronic Immune Thrombocytopenia (ITP) Expected in Q1 2018
Ticker: RIGL
Occurred on: Apr 17, 2018 -
Rigel (RIGL) Expects Full Results from Phase 2 Study of Fostamatinib in IgA Nephropathy in 2018
Ticker: RIGL
Occurred on: Apr 03, 2018 -
Rigel (RIGL) Expects Data on Fostamatinib in AIHA in 2017
Ticker: RIGL
Occurred on: Oct 03, 2017 -
Rigel (RIGL) Plans to Submit a New Drug Application for Fostamatinib in Immune Thrombocytopenic Purpura (ITP) in Q1 2017
Ticker: RIGL
Occurred on: Apr 17, 2017 -
Further Analysis of Rigel's (RIGL) Cohort 1 Phase 2 Data Evaluating Fostamatinib in IgA Nephropathy to be Presented in 2017
Ticker: RIGL
Occurred on: Jan 15, 2017 -
Phase 2 data of Fostamatinib for IgA nephropathy due by the end of 2016
Ticker: RIGL
Occurred on: Jan 11, 2017 -
Rigel (RIGL) Releases Preliminary Phase 2 Data on Fostamatinib in IgA Nephropathy
Ticker: RIGL
Occurred on: Jan 05, 2017 -
Interim update for Fostamatinib FIT Long Term Extension Study 049 in ITP expected in Oct/Nov 2016
Ticker: RIGL
Occurred on: Oct 20, 2016 -
Rigel's Phase 3 Data for Two Fostamantanib Studies Aimed at Treating Immune Thrombocytopenic Purpura Expected August, October of 2016
Ticker: RIGL
Occurred on: Aug 30, 2016 -
The results from the first study of Fostamatinib in ITP are expected in the middle of 2016
Ticker: RIGL
Occurred on: Aug 30, 2016 -
Phase 2 data of R348 for Chronic dry eye disease - as a result of patients with acute or chronic graft vs. host disease due 2016
Ticker: RIGL
Occurred on: Jul 12, 2016 -
Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP
Ticker: RIGL
Occurred on: Apr 01, 2016
Strategic Initiatives (RIGL)
